RGNX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
9.2M
-91.5%
108.0M
+1589.6%
6.4M
-78.9%
30.3M
+2.0%
29.7M
Cost of Revenue
1.1M
+9.5%
1.0M
-90.6%
11.1M
+86.8%
5.9M
+3.5%
5.7M
Gross Profit
8.0M
-92.5%
107.0M
+2385.3%
-4681000
-119.2%
24.4M
+1.7%
24.0M
Operating Expenses
43.6M
-44.0%
77.7M
-1.2%
78.7M
-4.1%
82.0M
+7.4%
76.4M
R&D
61.0M
+8.8%
56.1M
-2.2%
57.3M
-3.8%
59.6M
+6.3%
56.1M
SG&A
20.6M
-4.8%
21.6M
+1.5%
21.3M
-4.8%
22.4M
+10.5%
20.3M
Operating Income
-35534000
-221.4%
29.3M
+135.1%
-83362000
-44.6%
-57636000
-10.0%
-52411000
EBITDA
-70045000
-312.1%
33.0M
+141.5%
-79505000
-47.9%
-53767000
-10.8%
-48525000
Net Income
-40738000
-279.4%
22.7M
+125.2%
-90051000
-34.1%
-67149000
-8.4%
-61941000
EPS (Basic)
$-0.62
-244.2%
$0.43
+125.0%
$-1.72
-32.3%
$-1.30
-8.3%
$-1.20
EPS (Diluted)
$-0.62
-244.2%
$0.43
+125.0%
$-1.72
-32.3%
$-1.30
-8.3%
$-1.20
Shares (Diluted)
65.3M
+23.1%
53.0M
+1.1%
52.4M
+1.4%
51.7M
-0.0%
51.7M
REGENXBIO (RGNX) — Financials